COPENHAGEN, June 23 (Reuters) - Novo Nordisk

said on Monday it would halt its collaboration with U.S.

telehealth company Hims & Hers Health ( HIMS ) over the

distribution of the Danish company's blockbuster Wegovy weight

loss drugs.

The two companies had announced a collaboration in April for

Hims & Hers to sell Wegovy through a bundled offering on the

telehealth company's platform.

Earlier this month, Hims said that it will continue selling

"personalized" doses of Wegovy, starting at around $165 a month,

under rules allowing it for clinical reasons such as decreased

side effects.

Hims also sells liraglutide, a generic version of an older

Novo diabetes drug that also causes weight loss, as well as

branded Wegovy and Eli Lilly's ( LLY ) rival Zepbound.

Wall Street analysts have questioned whether Hims' offerings

actually qualify as "personalized" and say it is unclear if

Novo, which has said mass production of copies is breaking the

law, will allow it.

Hims & Hers was not immediately available for a comment

outside of the company's regular work hours.

A U.S. federal judge on Friday rejected a bid by compounding

pharmacies to allow them to continue making copies of Novo

Nordisk's weight-loss drugs Ozempic and Wegovy, upholding the

U.S. Food and Drug Administration's decision to remove the

drugs' active ingredient, semaglutide, from the shortage list.

"Efforts will continue to make authentic, FDA-approved

Wegovy directly available through NovoCare Pharmacy to select

telehealth organizations that share our commitment to safe and

effective medical treatment for patients," Novo said.

Novo's share price fell following the announcement,

extending an earlier decline to trade down 6.5% by 1315 GMT.

Shares of Hims and Hers fell 22% to $50.02 in U.S. premarket

hours.